1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

LINC 2018: More Data Demo IN.PACT's Impact, And Other Vasc-Device Findings

 
• By Reed Miller

The 2018 Leipzig Interventional Course (LINC), Jan. 30-Feb. 2, featured presentations of data from trials of peripheral stents from Biotronik and Veryan, TVA Medical's arteriovenous fistula, and drug-coated balloons from Medtronic, Boston Scientific, and Spectranetics.

view over Leipzig and its "Voelkerschlachtdenkmal" at dusk, Germany
Leipzig, Germany

The Leipzig Interventional Course is an annual four-day meeting in Leipzig, Germany featuring live cases, lectures, and poster presentations on vascular interventions to treat peripheral artery disease, carotid disease, deep vein thrombosis, aorto-iliac disease, and other non-coronary vessels. This year's meeting, held Jan. 30-Feb. 2, featured several presentations of new data from clinical trials of novel device therapies. Here are some of the highlights.

The IN.PACT SFA trial of Medtronic PLC's IN.PACT Admiral drug-coated peripheral angioplasty balloon is the first independently adjudicated, randomized, blinded trial to demonstrate the superiority of a drug-coated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By Marion Webb

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Digital Health And AI Tools Advance Cardiac Event Prediction, SCAI 2025 Data Show

 
• By Shubham Singh

Out-of-hospital cardiac arrest remains one of the most challenging and resource-intensive emergencies in cardiovascular care. At SCAI 2025, clinicians presented a novel algorithm that improved triage decisions and reduced unnecessary interventions.

More from Device Area

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By Marion Webb

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US

 
• By Natasha Barrow

SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.